Quantcast

Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union

April 28, 2009

S.MAMEDE DO CORONADO, Portugal and LONDON, April 28 /PRNewswire/ –

– New Option for Treatment of Epilepsy Patients With Partial Onset
Seizures

Bial-Portela & CA, S.A., (S. Mamede do Coronado, Portugal, President &
CEO Dr Luis Portela), and Eisai Europe Limited (London; Chairman & CEO Yutaka
Tsuchiya
), the European subsidiary of Eisai Co., Ltd. (Tokyo, President &
CEO: Haruo Naito), today announced that the novel once daily anti-epileptic
Zebinix(R)* (eslicarbazepine acetate) received marketing authorisation from
the European Commission as adjunctive therapy in adults with partial-onset
seizures, with or without secondary generalisation.

Epilepsy is one of the most common neurological diseases, affecting
approximately 1 in 100 people. Treatment of partial-onset seizures, the most
common type of epilepsy, remains a constant challenge and up to 40% of
patients with partial seizures do not achieve seizure control with current
anti-epileptics(1).

The efficacy, safety and tolerability of eslicarbazepine acetate (ESL)
has been demonstrated in three phase III double-blind, randomised
placebo-controlled trials in 1,049 patients with partial onset seizures(2-4).
For each randomised control trial patients were given the option of entering
a one year open label extension study.

ESL demonstrated significant and sustained reductions in seizure
frequency and significant increases in responder rates (greater than or equal
to 50% decrease in seizure frequency.) These studies also demonstrated that
patients continued to take ESL with retention rates ranging from 68-79% at
one year(5-7). The median daily dose throughout this one year treatment was
800mg. Treatment-emergent adverse events affecting >10% of patients in the
pivotal studies were dizziness, headache and somnolence(8).

The studies found that patients taking ESL also showed statistically
significant improvement in scores of health related quality of life measures
such as reduced ‘seizure worry’, improvements in ‘cognitive functioning’ and
reduced ‘medication effects’, all factors which significantly affect the
lives of patients living with epilepsy.(9-11)

ESL can be given as a true one tablet once a day regimen at its median
daily dose as defined in clinical trials as 800mg (5-7). It works by
selectively inhibiting the rapid firing of neurones. ESL interacts with site
two of the voltage-gated sodium channel, stabilising its inactive form and
preventing its return to the active open state, thereby reducing repetitive
neuronal firing. ESL has a much higher affinity for the inactivated state of
the channel compared with the resting state which means it is less likely to
interfere with normal neuronal function (12).

“A significant number of patients with partial-onset seizures remain
uncontrolled on existing epilepsy therapies and the inability to control
seizures can have a devastating impact on the quality of a patient’s day to
day life and functioning,” said Professor Christian Elger, Director and Head
of the Department of Epileptology at the University of Bonn, Germany and the
lead author of one of the pivotal studies – published earlier this year in
Epilepsia.

Under the terms of a deal with Bial announced in February this year,
Eisai received a sole license to market, promote and distribute ESL within
Europe**.

“The EU approval of Zebinix(R) represents a significant milestone for
Bial in our efforts to bring this novel treatment to patients with
partial-onset seizures”, said Luís Portela, President and Chief Executive
Officer of Bial. “We will work closely with our European partner Eisai to
launch Zebinix(R) across the EU during 2009 and into 2010.”

Yutaka Tsuchiya, Chairman & CEO of Eisai Europe said “The effective
treatment of patients with partial-onset seizures remains a major challenge
for clinicians and the carers of patients with epilepsy, and we are delighted
to be working with Bial towards bringing to patients such a promising new
treatment for epilepsy. Zebinix(R) joins our existing family of
anti-epileptics, which includes zonisamide and rufinamide and a new molecule
currently entering phase three clinical development studies. When launched,
Zebinix(R) will help us to fulfil our Corporate mission of ‘human health
care’ (hhc); to provide innovative, high quality medicines to meet the ever
changing unmet medical needs of patients and their families as well as health
care professionals.”

Notes to Editors

* Zebinix(R) is the EU trade name for eslicarbazepine acetate.

** European Territories

Austria, Belgium, Bulgaria, Czech Republic, Belarus, Bosnia, Croatia,
Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland,
Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Monaco,
Netherlands, Norway, Poland, Romania, Russia, Serbia, Slovakia, Slovenia,
Spain (co promotion with Bial from launch) Sweden, Switzerland, Turkey,
Ukraine and United Kingdom.

About epilepsy, partial-onset seizures and their treatment

Epilepsy is one of the most common neurological diseases, affecting
approximately 1 in 100 people.

Epilepsy is a chronic neurological disease characterised by abnormal
discharges of neuronal activity causing seizures. Clinically, these manifest
as convulsions or jerking of muscles. Depending on the seizure type, seizures
may be limited to one part of the body, or may be generalised to involve the
whole body. Patients may also experience abnormal sensations, altered
behaviour or altered consciousness. Epilepsy is a disorder with many possible
causes. Often the cause of epilepsy is unknown. However, anything that
disturbs the normal pattern of neuron activity – from illness to brain damage
to abnormal brain development, can lead to seizures.

Epilepsy is characterised by abnormal firing of impulses from nerve cells
in the brain. In partial-onset seizures, these bursts of electrical activity
are initially focused in specific areas of the brain, but may become more
generalised; the symptoms vary according to the affected areas. Nerve
impulses are triggered via voltage-gated sodium channels in the nerve cell
membrane.

Treatment of partial-onset seizures, the most common type of epilepsy,
presents a constant challenge – up to 40% of patients with partial-onset
seizures do not achieve seizure control with current anti-epileptic drugs.(1)

Furthermore, adverse events, such as lightheadedness (dizziness),
somnolence (sleepiness), and cognitive slowing, are highly prevalent with
existing anti-epileptic agents and may affect as many as 97% of patients.
Hence, there is a need for new anti-epileptic agents that offer effective
reduction in seizure frequency combined with a favourable safety profile.

About Eslicarbazepine Acetate

Eslicarbazepine acetate (ESL) is a novel voltage-gated sodium channel
blocker. It specifically targets the inactivated state of the ion channel,
preventing its return to the active state, and thereby reduces repetitive
neuronal firing. The efficacy of ESL has been demonstrated in 3 randomised,
placebo controlled studies in 1049 patients with refractory partial onset
seizures. ESL also significantly improved patient’s health related quality of
life (HRQoL) as measured by the QOLIE-31 score during a one year open label
extension of the above 3 studies. ESL is given orally once daily. ESL can be
used as an add-on to carbamazepine (one of the most commonly utilized
therapies for partial onset seizures) or with other anti-epileptics.

Clinical data

The EU approval was based on data from phase II and three phase III,
double-blind, randomised, placebo-controlled, multi-centre trials involving
1,192 patients from 23 countries. Patients had a history of at least four
partial seizures per month despite treatment with up to three concomitant
anti-epileptic drugs.

During the trials, patients were randomised to various dosages of ESL or
placebo and after a 2-week titration period, were assessed over a 12 week
maintenance period, with continued follow-up over a one year open-label
period.

Efficacy

Over the 12 week maintenance period, ESL 800mg and 1200mg once-daily
reduced seizure frequency by over one third,8 and was significantly more
effective than placebo. This significant decrease in seizure frequency was
sustained over the one-year open label treatment period and was consistent
regardless of baseline therapy.

Tolerability

The safety profile of ESL was favourable. The majority of treatment
related adverse events were mild or moderate in intensity. After 6 weeks of
treatment, there were no observed differences in the incidence of side
effects between patients treated with ESL and the placebo group.(8)

Quality of life and depressive symptoms

The effect of ESL on quality of life was assessed using the Quality of
Life Epilepsy Inventory-31 (QOLIE-31) scale. There was a statistically and
clinically significant improvement from baseline during long-term open-label
therapy, including a mean relative improvement in overall quality of life
(p<0.001 – p<0.01 across the three studies) and improvements in individual
elements of the QOLIE-31 scale including seizure worry, emotional wellbeing,
energy/fatigue, medication effects and social function.

Improvement in depressive symptoms was also measured using the Montgomery
Asberg Depression Rating Scale (MADRS). During long-term, open-label therapy,
ESL demonstrated a statistically significant improvement from baseline in the
overall MADRS score (p<0.0001) and individual domains of the MADRS scale
including pessimistic thoughts, concentration difficulties, apparent sadness
and inner tension.

These data were presented at the 8th European Congress on Epileptology
held in Berlin last September 2008 and at the Annual Meeting of the American
Epilepsy Society (AES) in December 2008, Seattle, WA, USA.

About Bial

Founded in 1924, Bial is an international pharmaceutical group with
products available in over 30 countries throughout four continents. BIAL is
the largest Portuguese pharmaceutical company and is based in S. Mamede do
Coronado, Portugal.

It is the partner of choice for many companies, having a strong presence
in the Iberian peninsula as well as in over 10 countries in Latin America and
in around 20 French or Portuguese speaking African countries.

Bial is strongly committed to therapeutic innovation investing
approximately 20% of its turnover in research and development every year. Key
research areas for BIAL are the central nervous system, the cardiovascular
system and allergology. Bial currently has several other innovative programs
under development, which the company expects to bring to the market within
the next years, thereby strengthening its position throughout Europe.

Further information about Bial can be found at http://www.bial.com

About Eisai

Eisai is one of the worlds leading R&D-based pharmaceutical companies,
that has defined its corporate mission as “giving first thought to patients
and their families and to increasing the benefits health care provides,”
which we call human health care (hhc).

    Eisai concentrates its R&D activities in three key areas

    - Integrative Neuroscience: Alzheimer's disease, multiple
    sclerosis, neuropathic pain, epilepsy, depression, etc
    - Integrative Oncology: Anticancer therapies; tumour regression,
    tumour suppression, antibodies, etc and Supportive cancer therapies; pain
    relief, nausea, etc
    - Vascular/Immunological Reaction: Acute coronary syndrome,
    atherothrombotic disease, sepsis, rheumatoid arthritis, psoriasis,
    Crohn's disease, etc

With operations in the U.S., Asia, Europe and its domestic home market of
Japan, we employ more than 10,000 people worldwide, and reported consolidated
sales of over GBP3.53 billion in FY2007, an increase of 8.9% year on year. In
Europe, Eisai undertakes sales and marketing operations in over 20 markets,
including the United Kingdom, France, Germany, Italy, Spain, Switzerland,
Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Czech
Republic
, Hungary, and Slovakia.

For further information please visit our web site http://www.eisai.co.jp

References:

1. Brodie MJ. Management strategies for refractory localization-related
seizures. Epilepsia 2001; 42(Suppl 3):27-30.

2. Elger C, Halász P, Maia J et al. Efficacy and safety of
eslicarbazepine acetate as adjunctive treatment in adults with refractory
partial-onset seizures: A randomized, double-blind, placebo-controlled,
parallel-group phase III study. Epilepsia 2009; 50(3):454-463.

3. Hufnagel A, Ben-Menachem E, Gabbai A et al. Efficacy and safety of
eslicarbazepine acetate as add-on treatment in adults with refractory
partial-onset seizures: BIA-2093-302 Study. Poster presented at the 8th
European Congress on Epileptology, 21-25 September 2008, Berlin, Germany.

4. Lopes-Lima J, Gil-Nagel A, Maia J et al. Efficacy and safety of
eslicarbazepine acetate as add-on treatment in adults with refractory
partial-onset seizures: BIA-2093-303 Study. Poster presented at the 8th
European Congress on Epileptology, 21-25 September 2008, Berlin, Germany.

5. Halász P, Elger C, Guekht A et al. Long-Term Treatment of Partial
Epilepsy with Eslicarbazepine Acetate (ESL): Results of a One-Year Open-Label
Extension to Study BIA-2093-301. Poster presented at the American Epilepsy
Society (AES) Congress, 5-9 December 2008, Seattle, WA, USA.

6. Gabbai AA, Ben-Menachem E, Maia J et al. Long-Term Treatment of
Partial Epilepsy with Eslicarbazepine Acetate (ESL): Results of a One-Year
Open-Label Extension to Study BIA-2093-302. Poster presented at the American
Epilepsy Society (AES) Congress, 5-9 December 2008, Seattle, WA, USA.

7. Lopes-Lima J, Gil-Nagel A, Maia J et al. Long-Term Treatment of
Partial Epilepsy with Eslicarbazepine Acetate (ESL): Results of a One-Year
Open-Label Extension to Study BIA-2093-303. Poster presented at the American
Epilepsy Society (AES) Congress, 5-9 December 2008, Seattle, WA, USA

8. Elger C, French J, Halasz P. et al. Evaluation of Eslicarbazepine
Acetate as Add-On Treatment in Patients with Partial-Onset Seizures: Pooled
Analysis of Three Double-Blind Phase III Clinical Studies. Poster presented
at the American Epilepsy Society (AES) Congress, 5-9 December 2008, Seattle,
WA
, USA.

9. Cramer J, Elger C, Halász P et al. An Evaluation of Quality of Life
and Depressive Symptoms During Long-Term Treatment with Eslicarbazepine
Acetate: BIA-2093-301 Study.QOL 301. Poster presented at the American
Epilepsy Society (AES) Congress, 5-9 December 2008, Seattle, WA, USA.

10. Soares-da-Silva P, Martins-da-Silva A, Gabbai AA et al. An Evaluation
of Quality of Life and Depressive Symptoms During Long-Term Treatment with
Eslicarbazepine Acetate: BIA-2093-302 Study. Poster presented at the American
Epilepsy Society (AES) Congress, 5-9 December 2008, Seattle, WA, USA.

11. Pereira H, Lopes-Lima J, Gil-Nagel A et al. An Evaluation of Quality
of Life and Depressive Symptoms During Long-Term Treatment with
Eslicarbazepine Acetate: BIA-2093-303 Study. Poster presented at the American
Epilepsy Society (AES) Congress, 5-9 December 2008, Seattle, WA, USA.

    12. Bonifacio MJ, et al. Epilepsia 2001;42(5):600-608

    For further information please contact

    Francisco Osório, BIAL
    +351-22-9866100
    +351-96-346-9968

    Andrew Day, EISAI
    +44(0)20-8600-1400
    +44(0)7973-411-419

SOURCE Bial and Eisai


Source: newswire



comments powered by Disqus